Nano ChemOthersapy
Nano ChemOthersapy market is segmented by players, region (country), by Type and by Application. ... Read More
Global Cancer Antibody Drug Conjugates Market Research Report 2024
1 Cancer Antibody Drug Conjugates Market Overview
1.1 Product Overview and Scope of Cancer Antibody Drug Conjugates
1.2 Cancer Antibody Drug Conjugates Segment by Type
1.2.1 Global Cancer Antibody Drug Conjugates Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 First & Second Generation ADCs
1.2.3 Third Generation ADCs
1.3 Cancer Antibody Drug Conjugates Segment by Application
1.3.1 Global Cancer Antibody Drug Conjugates Sales Comparison by Application: (2022-2028)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Cancer Antibody Drug Conjugates Market Size Estimates and Forecasts
1.4.1 Global Cancer Antibody Drug Conjugates Revenue 2017-2028
1.4.2 Global Cancer Antibody Drug Conjugates Sales 2017-2028
1.4.3 Cancer Antibody Drug Conjugates Market Size by Region: 2017 Versus 2021 Versus 2028
2 Cancer Antibody Drug Conjugates Market Competition by Manufacturers
2.1 Global Cancer Antibody Drug Conjugates Sales Market Share by Manufacturers (2017-2022)
2.2 Global Cancer Antibody Drug Conjugates Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Cancer Antibody Drug Conjugates Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Cancer Antibody Drug Conjugates Manufacturing Sites, Area Served, Product Type
2.5 Cancer Antibody Drug Conjugates Market Competitive Situation and Trends
2.5.1 Cancer Antibody Drug Conjugates Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Cancer Antibody Drug Conjugates Players Market Share by Revenue
2.5.3 Global Cancer Antibody Drug Conjugates Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cancer Antibody Drug Conjugates Retrospective Market Scenario by Region
3.1 Global Cancer Antibody Drug Conjugates Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Cancer Antibody Drug Conjugates Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Cancer Antibody Drug Conjugates Market Facts & Figures by Country
3.3.1 North America Cancer Antibody Drug Conjugates Sales by Country
3.3.2 North America Cancer Antibody Drug Conjugates Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Cancer Antibody Drug Conjugates Market Facts & Figures by Country
3.4.1 Europe Cancer Antibody Drug Conjugates Sales by Country
3.4.2 Europe Cancer Antibody Drug Conjugates Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Cancer Antibody Drug Conjugates Market Facts & Figures by Region
3.5.1 Asia Pacific Cancer Antibody Drug Conjugates Sales by Region
3.5.2 Asia Pacific Cancer Antibody Drug Conjugates Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Cancer Antibody Drug Conjugates Market Facts & Figures by Country
3.6.1 Latin America Cancer Antibody Drug Conjugates Sales by Country
3.6.2 Latin America Cancer Antibody Drug Conjugates Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Cancer Antibody Drug Conjugates Market Facts & Figures by Country
3.7.1 Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country
3.7.2 Middle East and Africa Cancer Antibody Drug Conjugates Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Cancer Antibody Drug Conjugates Historic Market Analysis by Type
4.1 Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2017-2022)
4.2 Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2017-2022)
4.3 Global Cancer Antibody Drug Conjugates Price by Type (2017-2022)
5 Global Cancer Antibody Drug Conjugates Historic Market Analysis by Application
5.1 Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2017-2022)
5.2 Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2017-2022)
5.3 Global Cancer Antibody Drug Conjugates Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Novartis Cancer Antibody Drug Conjugates Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Merck Cancer Antibody Drug Conjugates Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Roche Cancer Antibody Drug Conjugates Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 AbbVie
6.4.1 AbbVie Corporation Information
6.4.2 AbbVie Description and Business Overview
6.4.3 AbbVie Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.4.4 AbbVie Cancer Antibody Drug Conjugates Product Portfolio
6.4.5 AbbVie Recent Developments/Updates
6.5 UCB
6.5.1 UCB Corporation Information
6.5.2 UCB Description and Business Overview
6.5.3 UCB Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.5.4 UCB Cancer Antibody Drug Conjugates Product Portfolio
6.5.5 UCB Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Stem CentRx
6.6.1 Stem CentRx Corporation Information
6.6.2 Stem CentRx Description and Business Overview
6.6.3 Stem CentRx Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Stem CentRx Cancer Antibody Drug Conjugates Product Portfolio
6.7.5 Stem CentRx Recent Developments/Updates
6.8 Biogen Idec
6.8.1 Biogen Idec Corporation Information
6.8.2 Biogen Idec Description and Business Overview
6.8.3 Biogen Idec Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Biogen Idec Cancer Antibody Drug Conjugates Product Portfolio
6.8.5 Biogen Idec Recent Developments/Updates
6.9 Nordic Nanovector
6.9.1 Nordic Nanovector Corporation Information
6.9.2 Nordic Nanovector Description and Business Overview
6.9.3 Nordic Nanovector Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Nordic Nanovector Cancer Antibody Drug Conjugates Product Portfolio
6.9.5 Nordic Nanovector Recent Developments/Updates
6.10 Millennium
6.10.1 Millennium Corporation Information
6.10.2 Millennium Description and Business Overview
6.10.3 Millennium Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Millennium Cancer Antibody Drug Conjugates Product Portfolio
6.10.5 Millennium Recent Developments/Updates
6.11 Biotest AG
6.11.1 Biotest AG Corporation Information
6.11.2 Biotest AG Cancer Antibody Drug Conjugates Description and Business Overview
6.11.3 Biotest AG Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Biotest AG Cancer Antibody Drug Conjugates Product Portfolio
6.11.5 Biotest AG Recent Developments/Updates
6.12 PDL BioPharma
6.12.1 PDL BioPharma Corporation Information
6.12.2 PDL BioPharma Cancer Antibody Drug Conjugates Description and Business Overview
6.12.3 PDL BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.12.4 PDL BioPharma Cancer Antibody Drug Conjugates Product Portfolio
6.12.5 PDL BioPharma Recent Developments/Updates
6.13 Progenics Pharmaceuticals
6.13.1 Progenics Pharmaceuticals Corporation Information
6.13.2 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Description and Business Overview
6.13.3 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product Portfolio
6.13.5 Progenics Pharmaceuticals Recent Developments/Updates
6.14 Seattle Genetics
6.14.1 Seattle Genetics Corporation Information
6.14.2 Seattle Genetics Cancer Antibody Drug Conjugates Description and Business Overview
6.14.3 Seattle Genetics Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Seattle Genetics Cancer Antibody Drug Conjugates Product Portfolio
6.14.5 Seattle Genetics Recent Developments/Updates
6.15 Viventia Biotechnologies
6.15.1 Viventia Biotechnologies Corporation Information
6.15.2 Viventia Biotechnologies Cancer Antibody Drug Conjugates Description and Business Overview
6.15.3 Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Viventia Biotechnologies Cancer Antibody Drug Conjugates Product Portfolio
6.15.5 Viventia Biotechnologies Recent Developments/Updates
6.16 AbGenomics Corporation
6.16.1 AbGenomics Corporation Corporation Information
6.16.2 AbGenomics Corporation Cancer Antibody Drug Conjugates Description and Business Overview
6.16.3 AbGenomics Corporation Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.16.4 AbGenomics Corporation Cancer Antibody Drug Conjugates Product Portfolio
6.16.5 AbGenomics Corporation Recent Developments/Updates
6.17 Helix BioPharma
6.17.1 Helix BioPharma Corporation Information
6.17.2 Helix BioPharma Cancer Antibody Drug Conjugates Description and Business Overview
6.17.3 Helix BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Helix BioPharma Cancer Antibody Drug Conjugates Product Portfolio
6.17.5 Helix BioPharma Recent Developments/Updates
7 Cancer Antibody Drug Conjugates Manufacturing Cost Analysis
7.1 Cancer Antibody Drug Conjugates Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Cancer Antibody Drug Conjugates
7.4 Cancer Antibody Drug Conjugates Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Cancer Antibody Drug Conjugates Distributors List
8.3 Cancer Antibody Drug Conjugates Customers
9 Cancer Antibody Drug Conjugates Market Dynamics
9.1 Cancer Antibody Drug Conjugates Industry Trends
9.2 Cancer Antibody Drug Conjugates Market Drivers
9.3 Cancer Antibody Drug Conjugates Market Challenges
9.4 Cancer Antibody Drug Conjugates Market Restraints
10 Global Market Forecast
10.1 Cancer Antibody Drug Conjugates Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Cancer Antibody Drug Conjugates by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Cancer Antibody Drug Conjugates by Type (2023-2028)
10.2 Cancer Antibody Drug Conjugates Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Cancer Antibody Drug Conjugates by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Cancer Antibody Drug Conjugates by Application (2023-2028)
10.3 Cancer Antibody Drug Conjugates Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Cancer Antibody Drug Conjugates by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Cancer Antibody Drug Conjugates by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Cancer Antibody Drug Conjugates Sales Growth Rate Comparison by Type (2022-2028) & (K Dose) & (US$ Million)
Table 2. Global Cancer Antibody Drug Conjugates Sales Growth Rate Comparison by Application (2022-2028) & (K Dose) & (US$ Million)
Table 3. Global Cancer Antibody Drug Conjugates Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Cancer Antibody Drug Conjugates Market Competitive Situation by Manufacturers in 2021
Table 5. Global Cancer Antibody Drug Conjugates Sales (K Dose) of Key Manufacturers (2017-2022)
Table 6. Global Cancer Antibody Drug Conjugates Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Cancer Antibody Drug Conjugates Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Cancer Antibody Drug Conjugates Average Price (USD/Dose) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Cancer Antibody Drug Conjugates Manufacturing Sites and Area Served
Table 11. Manufacturers Cancer Antibody Drug Conjugates Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Cancer Antibody Drug Conjugates by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Antibody Drug Conjugates as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Cancer Antibody Drug Conjugates Sales by Region (2017-2022) & (K Dose)
Table 16. Global Cancer Antibody Drug Conjugates Sales Market Share by Region (2017-2022)
Table 17. Global Cancer Antibody Drug Conjugates Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region (2017-2022)
Table 19. North America Cancer Antibody Drug Conjugates Sales by Country (2017-2022) & (K Dose)
Table 20. North America Cancer Antibody Drug Conjugates Sales Market Share by Country (2017-2022)
Table 21. North America Cancer Antibody Drug Conjugates Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Cancer Antibody Drug Conjugates Revenue Market Share by Country (2017-2022)
Table 23. Europe Cancer Antibody Drug Conjugates Sales by Country (2017-2022) & (K Dose)
Table 24. Europe Cancer Antibody Drug Conjugates Sales Market Share by Country (2017-2022)
Table 25. Europe Cancer Antibody Drug Conjugates Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Cancer Antibody Drug Conjugates Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Cancer Antibody Drug Conjugates Sales by Region (2017-2022) & (K Dose)
Table 28. Asia Pacific Cancer Antibody Drug Conjugates Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Cancer Antibody Drug Conjugates Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Cancer Antibody Drug Conjugates Revenue Market Share by Region (2017-2022)
Table 31. Latin America Cancer Antibody Drug Conjugates Sales by Country (2017-2022) & (K Dose)
Table 32. Latin America Cancer Antibody Drug Conjugates Sales Market Share by Country (2017-2022)
Table 33. Latin America Cancer Antibody Drug Conjugates Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Cancer Antibody Drug Conjugates Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2017-2022) & (K Dose)
Table 36. Middle East and Africa Cancer Antibody Drug Conjugates Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Cancer Antibody Drug Conjugates Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Cancer Antibody Drug Conjugates Revenue Market Share by Country (2017-2022)
Table 39. Global Cancer Antibody Drug Conjugates Sales by Type (2017-2022) & (K Dose)
Table 40. Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2017-2022)
Table 41. Global Cancer Antibody Drug Conjugates Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Cancer Antibody Drug Conjugates Revenue Share by Type (2017-2022)
Table 43. Global Cancer Antibody Drug Conjugates Price by Type (2017-2022) & (USD/Dose)
Table 44. Global Cancer Antibody Drug Conjugates Sales (K Dose) by Application (2017-2022)
Table 45. Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2017-2022)
Table 46. Global Cancer Antibody Drug Conjugates Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Cancer Antibody Drug Conjugates Revenue Share by Application (2017-2022)
Table 48. Global Cancer Antibody Drug Conjugates Price by Application (2017-2022) & (USD/Dose)
Table 49. Novartis Corporation Information
Table 50. Novartis Description and Business Overview
Table 51. Novartis Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 52. Novartis Cancer Antibody Drug Conjugates Product
Table 53. Novartis Recent Developments/Updates
Table 54. Merck Corporation Information
Table 55. Merck Description and Business Overview
Table 56. Merck Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 57. Merck Cancer Antibody Drug Conjugates Product
Table 58. Merck Recent Developments/Updates
Table 59. Roche Corporation Information
Table 60. Roche Description and Business Overview
Table 61. Roche Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 62. Roche Cancer Antibody Drug Conjugates Product
Table 63. Roche Recent Developments/Updates
Table 64. AbbVie Corporation Information
Table 65. AbbVie Description and Business Overview
Table 66. AbbVie Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 67. AbbVie Cancer Antibody Drug Conjugates Product
Table 68. AbbVie Recent Developments/Updates
Table 69. UCB Corporation Information
Table 70. UCB Description and Business Overview
Table 71. UCB Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 72. UCB Cancer Antibody Drug Conjugates Product
Table 73. UCB Recent Developments/Updates
Table 74. Bristol-Myers Squibb Corporation Information
Table 75. Bristol-Myers Squibb Description and Business Overview
Table 76. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 77. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product
Table 78. Bristol-Myers Squibb Recent Developments/Updates
Table 79. Stem CentRx Corporation Information
Table 80. Stem CentRx Description and Business Overview
Table 81. Stem CentRx Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 82. Stem CentRx Cancer Antibody Drug Conjugates Product
Table 83. Stem CentRx Recent Developments/Updates
Table 84. Biogen Idec Corporation Information
Table 85. Biogen Idec Description and Business Overview
Table 86. Biogen Idec Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 87. Biogen Idec Cancer Antibody Drug Conjugates Product
Table 88. Biogen Idec Recent Developments/Updates
Table 89. Nordic Nanovector Corporation Information
Table 90. Nordic Nanovector Description and Business Overview
Table 91. Nordic Nanovector Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 92. Nordic Nanovector Cancer Antibody Drug Conjugates Product
Table 93. Nordic Nanovector Recent Developments/Updates
Table 94. Millennium Corporation Information
Table 95. Millennium Description and Business Overview
Table 96. Millennium Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 97. Millennium Cancer Antibody Drug Conjugates Product
Table 98. Millennium Recent Developments/Updates
Table 99. Biotest AG Corporation Information
Table 100. Biotest AG Description and Business Overview
Table 101. Biotest AG Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 102. Biotest AG Cancer Antibody Drug Conjugates Product
Table 103. Biotest AG Recent Developments/Updates
Table 104. PDL BioPharma Corporation Information
Table 105. PDL BioPharma Description and Business Overview
Table 106. PDL BioPharma Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 107. PDL BioPharma Cancer Antibody Drug Conjugates Product
Table 108. PDL BioPharma Recent Developments/Updates
Table 109. Progenics Pharmaceuticals Corporation Information
Table 110. Progenics Pharmaceuticals Description and Business Overview
Table 111. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 112. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product
Table 113. Progenics Pharmaceuticals Recent Developments/Updates
Table 114. Seattle Genetics Corporation Information
Table 115. Seattle Genetics Description and Business Overview
Table 116. Seattle Genetics Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 117. Seattle Genetics Cancer Antibody Drug Conjugates Product
Table 118. Seattle Genetics Recent Developments/Updates
Table 119. Viventia Biotechnologies Corporation Information
Table 120. Viventia Biotechnologies Description and Business Overview
Table 121. Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 122. Viventia Biotechnologies Cancer Antibody Drug Conjugates Product
Table 123. Viventia Biotechnologies Recent Developments/Updates
Table 124. AbGenomics Corporation Corporation Information
Table 125. AbGenomics Corporation Description and Business Overview
Table 126. AbGenomics Corporation Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 127. AbGenomics Corporation Cancer Antibody Drug Conjugates Product
Table 128. AbGenomics Corporation Recent Developments/Updates
Table 129. Helix BioPharma Corporation Information
Table 130. Helix BioPharma Description and Business Overview
Table 131. Helix BioPharma Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 132. Helix BioPharma Cancer Antibody Drug Conjugates Product
Table 133. Helix BioPharma Recent Developments/Updates
Table 134. Production Base and Market Concentration Rate of Raw Material
Table 135. Key Suppliers of Raw Materials
Table 136. Cancer Antibody Drug Conjugates Distributors List
Table 137. Cancer Antibody Drug Conjugates Customers List
Table 138. Cancer Antibody Drug Conjugates Market Trends
Table 139. Cancer Antibody Drug Conjugates Market Drivers
Table 140. Cancer Antibody Drug Conjugates Market Challenges
Table 141. Cancer Antibody Drug Conjugates Market Restraints
Table 142. Global Cancer Antibody Drug Conjugates Sales Forecast by Type (2023-2028) & (K Dose)
Table 143. Global Cancer Antibody Drug Conjugates Sales Market Share Forecast by Type (2023-2028)
Table 144. Global Cancer Antibody Drug Conjugates Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 145. Global Cancer Antibody Drug Conjugates Revenue Market Share Forecast by Type (2023-2028)
Table 146. Global Cancer Antibody Drug Conjugates Sales Forecast by Application (2023-2028) & (K Dose)
Table 147. Global Cancer Antibody Drug Conjugates Sales Market Share Forecast by Application (2023-2028)
Table 148. Global Cancer Antibody Drug Conjugates Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 149. Global Cancer Antibody Drug Conjugates Revenue Market Share Forecast by Application (2023-2028)
Table 150. Global Cancer Antibody Drug Conjugates Sales Forecast by Region (2023-2028) & (K Dose)
Table 151. Global Cancer Antibody Drug Conjugates Sales Market Share Forecast by Region (2023-2028)
Table 152. Global Cancer Antibody Drug Conjugates Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 153. Global Cancer Antibody Drug Conjugates Revenue Market Share Forecast by Region (2023-2028)
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Cancer Antibody Drug Conjugates
Figure 2. Global Cancer Antibody Drug Conjugates Market Share by Type in 2021 & 2028
Figure 3. First & Second Generation ADCs Product Picture
Figure 4. Third Generation ADCs Product Picture
Figure 5. Global Cancer Antibody Drug Conjugates Market Share by Application in 2021 & 2028
Figure 6. Hospitals
Figure 7. Clinics
Figure 8. Others
Figure 9. Global Cancer Antibody Drug Conjugates Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 10. Global Cancer Antibody Drug Conjugates Market Size (2017-2028) & (US$ Million)
Figure 11. Global Cancer Antibody Drug Conjugates Sales (2017-2028) & (K Dose)
Figure 12. Cancer Antibody Drug Conjugates Sales Share by Manufacturers in 2021
Figure 13. Global Cancer Antibody Drug Conjugates Revenue Share by Manufacturers in 2021
Figure 14. The Global 5 and 10 Largest Cancer Antibody Drug Conjugates Players: Market Share by Revenue in 2021
Figure 15. Cancer Antibody Drug Conjugates Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 16. Global Cancer Antibody Drug Conjugates Sales Market Share by Region (2017-2022)
Figure 17. Global Cancer Antibody Drug Conjugates Sales Market Share by Region in 2021
Figure 18. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region (2017-2022)
Figure 19. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region in 2021
Figure 20. U.S. Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Canada Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. Germany Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. France Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. U.K. Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Italy Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Russia Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. China Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Japan Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. South Korea Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. India Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. Australia Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Taiwan Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Indonesia Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Thailand Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Malaysia Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Philippines Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Vietnam Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Mexico Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Brazil Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Argentina Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Turkey Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Saudi Arabia Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. U.A.E Cancer Antibody Drug Conjugates Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Sales Market Share of Cancer Antibody Drug Conjugates by Type (2017-2022)
Figure 45. Manufacturing Cost Structure of Cancer Antibody Drug Conjugates
Figure 46. Manufacturing Process Analysis of Cancer Antibody Drug Conjugates
Figure 47. Cancer Antibody Drug Conjugates Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Novartis Merck Roche AbbVie UCB Bristol-Myers Squibb Stem CentRx Biogen Idec Nordic Nanovector Millennium Biotest AG PDL BioPharma Progenics Pharmaceuticals Seattle Genetics Viventia Biotechnologies AbGenomics Corporation Helix BioPharma